Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter.
Adenocarcinoma of Lung
/ genetics
Animals
Cell Line, Tumor
Cell Proliferation
/ physiology
Disease Progression
Heterografts
Humans
Interleukin-6
/ genetics
Lung Neoplasms
/ genetics
Mice
Mice, Nude
Promoter Regions, Genetic
RNA, Long Noncoding
/ genetics
STAT3 Transcription Factor
/ genetics
Survival Rate
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
08
11
2020
accepted:
23
03
2021
revised:
09
03
2021
pubmed:
17
4
2021
medline:
13
1
2022
entrez:
16
4
2021
Statut:
ppublish
Résumé
Long non-coding RNAs (lncRNAs) are emerging as a new class of regulators for a variety of biological processes and have been suggested to play pivotal roles in cancer development and progression. Our current study found that a lncRNA, designated enhancing IL-6/STAT3 signaling activation (LEISA, ENST00000603468), functioned as an oncogenic lncRNA in lung adenocarcinoma (LAD), a major form of non-small cell lung carcinoma, which is one of the most frequently diagnosed malignancies with high morbidity and mortality worldwide, and was involved in the regulation of STAT3 induced IL-6 transcription. Our data showed that LEISA was highly expressed in, and correlated with the clinical progression and prognosis of LAD. Ectopic expression of LEISA promoted the proliferation and suppressed apoptosis of LAD cells in vitro and in vivo. Mechanistically, we demonstrated that LEISA recruited STAT3 to bind the promoter of IL-6 and upregulated IL-6 expression. Taken together, our work identifies LEISA as a potential diagnostic biomarker and therapeutic target for LAD.
Identifiants
pubmed: 33859372
doi: 10.1038/s41388-021-01769-7
pii: 10.1038/s41388-021-01769-7
doi:
Substances chimiques
IL6 protein, human
0
Interleukin-6
0
RNA, Long Noncoding
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3449-3459Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer J clinicians. 2018;68:394–424.
Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol therapeutics. 2020;206:107438.
doi: 10.1016/j.pharmthera.2019.107438
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Cancer Netw: JNCCN. 2015;13:515–24.
doi: 10.6004/jnccn.2015.0071
Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106:1624–33.
pubmed: 16518827
doi: 10.1002/cncr.21778
Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298–307.
pubmed: 23498938
pmcid: 3651923
doi: 10.1016/j.cell.2013.02.012
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–8.
pubmed: 22955620
pmcid: 3684276
doi: 10.1038/nature11233
Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23:1494–504.
pubmed: 19571179
pmcid: 3152381
doi: 10.1101/gad.1800909
Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Sci (N. Y, NY). 2010;329:689–93.
doi: 10.1126/science.1192002
Lai F, Orom UA, Cesaroni M, Beringer M, Taatjes DJ, Blobel GA, et al. Activating RNAs associate with Mediator to enhance chromatin architecture and transcription. Nature. 2013;494:497–501.
pubmed: 23417068
pmcid: 4109059
doi: 10.1038/nature11884
Fang L, Wu S, Zhu X, Cai J, Wu J, He Z, et al. MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-β pathway in NSCLC. Oncogene. 2019;38:896–912.
pubmed: 30181549
doi: 10.1038/s41388-018-0484-9
Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193:651–69.
pubmed: 23463798
pmcid: 3583990
doi: 10.1534/genetics.112.146704
Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.
pubmed: 28701486
doi: 10.1158/0008-5472.CAN-16-2634
pmcid: 8330958
Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–7.
pubmed: 28604750
pmcid: 6450570
doi: 10.1038/onc.2017.184
Guan H, Zhu T, Wu S, Liu S, Liu B, Wu J, et al. Long noncoding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/β-catenin signaling. Proc Natl Acad Sci USA. 2019;116:14019–28.
pubmed: 31235588
doi: 10.1073/pnas.1900997116
pmcid: 6628810
Silva A, Bullock M, Calin G. The clinical relevance of long non-coding RNAs in cancer. Cancers. 2015;7:2169–82.
pubmed: 26516918
pmcid: 4695884
doi: 10.3390/cancers7040884
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
pubmed: 18650914
doi: 10.1038/nature07205
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
pubmed: 12490959
pmcid: 2803035
doi: 10.1038/nature01322
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. The. J Clin Investig. 2007;117:3846–56.
pubmed: 18060032
doi: 10.1172/JCI31871
pmcid: 2096430
Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18:773–89.
pubmed: 30254251
doi: 10.1038/s41577-018-0066-7
Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10:720–7.
pubmed: 25136784
doi: 10.1038/nrrheum.2014.127
Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2:288–94.
pubmed: 24764575
doi: 10.1158/2326-6066.CIR-14-0022
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.
pubmed: 19851315
pmcid: 4856025
doi: 10.1038/nrc2734
Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA. 2001;98:9824–9.
pubmed: 11504947
doi: 10.1073/pnas.171320598
pmcid: 55537
Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol cancer therapeutics. 2011;10:481–94.
doi: 10.1158/1535-7163.MCT-10-0502
Vinocha A, Grover RK, Deepak R. Clinical significance of interleukin-6 in diagnosis of lung, oral, esophageal, and gall bladder carcinomas. J cancer Res therapeutics. 2018;14:S758–s60.
doi: 10.4103/0973-1482.183217
Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105.
pubmed: 14964307
doi: 10.1038/nrc1275
Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50:1007–23.
pubmed: 30995492
doi: 10.1016/j.immuni.2019.03.026
Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234–48.
pubmed: 29405201
pmcid: 5858971
doi: 10.1038/nrclinonc.2018.8
Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54–74.
pubmed: 24552665
doi: 10.1016/j.smim.2014.01.001
Lederle W, Depner S, Schnur S, Obermueller E, Catone N, Just A, et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int J cancer. 2011;128:2803–14.
pubmed: 20726000
doi: 10.1002/ijc.25621
Yoon S, Woo SU, Kang JH, Kim K, Kwon MH, Park S, et al. STAT3 transcriptional factor activated by reactive oxygen species induces IL-6 in starvation-induced autophagy of cancer cells. Autophagy. 2010;6:1125–38.
pubmed: 20930550
doi: 10.4161/auto.6.8.13547
Yoon S, Woo SU, Kang JH, Kim K, Shin HJ, Gwak HS, et al. NF-κB and STAT3 cooperatively induce IL-6 in starved cancer cells. Oncogene. 2012;31:3467–81.
pubmed: 22105366
doi: 10.1038/onc.2011.517
Chang R, Song L, Xu Y, Wu Y, Dai C, Wang X, et al. Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis. Nat Commun. 2018;9:3486.
pubmed: 30154439
pmcid: 6113304
doi: 10.1038/s41467-018-05852-8
Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T, Miyake T, et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature. 2009;458:1185–90.
pubmed: 19322177
doi: 10.1038/nature07924
Uehata T, Iwasaki H, Vandenbon A, Matsushita K, Hernandez-Cuellar E, Kuniyoshi K, et al. Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation. Cell. 2013;153:1036–49.
pubmed: 23706741
doi: 10.1016/j.cell.2013.04.034
Wang X, Sun W, Shen W, Xia M, Chen C, Xiang D, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol. 2016;64:1283–94.
pubmed: 26812074
doi: 10.1016/j.jhep.2016.01.019
Wang J, Zhou J, Jiang C, Zheng J, Namba H, Chi P, et al. LNRRIL-6, a novel long noncoding RNA, protects colorectal cancer cells by activating the IL-6-STAT3 pathway. Mol Oncol. 2019;13:2344–60.
pubmed: 31246342
pmcid: 6822249
doi: 10.1002/1878-0261.12538
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–14.
pubmed: 21925379
pmcid: 3199020
doi: 10.1016/j.molcel.2011.08.018
Hung T, Chang HY. Long noncoding RNA in genome regulation: prospects and mechanisms. RNA Biol. 2010;7:582–5.
pubmed: 20930520
pmcid: 3073254
doi: 10.4161/rna.7.5.13216
Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.
pubmed: 29373828
pmcid: 5978744
Engreitz JM, Haines JE, Perez EM, Munson G, Chen J, Kane M, et al. Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature. 2016;539:452–5.
pubmed: 27783602
pmcid: 6853796
doi: 10.1038/nature20149
Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129:1311–23.
pubmed: 17604720
pmcid: 2084369
doi: 10.1016/j.cell.2007.05.022
Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–63.
pubmed: 27070700
pmcid: 4831138
doi: 10.1016/j.ccell.2016.03.010
Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3ʹ UTRs via Alu elements. Nature. 2011;470:284–8.
pubmed: 21307942
pmcid: 3073508
doi: 10.1038/nature09701
Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, et al. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 2013;73:5402–15.
pubmed: 23856247
doi: 10.1158/0008-5472.CAN-13-0297
Iioka H, Loiselle D, Haystead TA, Macara IG. Efficient detection of RNA-protein interactions using tethered RNAs. Nucleic Acids Res. 2011;39:e53.
pubmed: 21300640
pmcid: 3082893
doi: 10.1093/nar/gkq1316
Xing YH, Yao RW, Zhang Y, Guo CJ, Jiang S, Xu G, et al. SLERT regulates DDX21 rings associated with Pol I transcription. Cell. 2017;169:664–78. e16.
pubmed: 28475895
doi: 10.1016/j.cell.2017.04.011
Deng SJ, Chen HY, Zeng Z, Deng S, Zhu S, Ye Z, et al. Nutrient stress-dysregulated antisense lncRNA GLS-AS impairs GLS-mediated metabolism and represses pancreatic cancer progression. Cancer Res. 2019;79:1398–412.
pubmed: 30563888
doi: 10.1158/0008-5472.CAN-18-0419
Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat Protoc. 2006;1:729–48.
pubmed: 17406303
pmcid: 3004291
doi: 10.1038/nprot.2006.98
Ying Z, Tian H, Li Y, Lian R, Li W, Wu S, et al. CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling. The. J Clin Investig. 2017;127:1725–40.
pubmed: 28375158
doi: 10.1172/JCI90439
pmcid: 5409794
Cai J, Li R, Xu X, Zhang L, Lian R, Fang L, et al. CK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy. Nat cell Biol. 2018;20:465–78.
pubmed: 29593330
doi: 10.1038/s41556-018-0065-8